Clinical and Genetic Characteristics of Opioid Addiction in Chronic Pain
The goal of this project is to develop a profile of patients' risk factors for opioid addiction when receiving opioid therapy for chronic pain. This project will investigate various influences in the development of addiction in 2,000 individuals, with history of chronic pain, who have undergone treatment for addiction to ...
A study for people looking to transition from Buprenorphine maintenance to VIVITROL
Up to 9 weeks, including Screening (up to 3 weeks), up to 2 weeks for Lead-in Period and residential Treatment Period receiving decreasing doses of Buprenorphine and increasing doses of either active or placebo Naltrexone, 4-5 days for VIVITROL induction and post-VIVITROL monitoring, and a 4-week outpatient follow-up period.